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Prostate cancera b s t r a c t
Introduction: Understanding the topographical distribution of prostate cancer (PCa) foci is necessary to
optimize the biopsy strategy. This study was done to develop a technical approach that facilitates the
analysis of the topographical distribution of PCa foci and related pathological findings (i.e., Gleason score
and foci dimensions) in prostatectomy specimens.
Material & methods: The topographical distribution of PCa foci and related pathologic evaluations were
documented using the cMDX documentation system. The project was performed in three steps. First,
we analyzed the document architecture of cMDX, including textual and graphical information. Second,
we developed a data model supporting the topographic analysis of PCa foci and related pathologic param-
eters. Finally, we retrospectively evaluated the analysis model in 168 consecutive prostatectomy
specimens of men diagnosed with PCa who underwent total prostate removal. The distribution of PCa
foci were analyzed and visualized in a heat map. The color depth of the heat map was reduced to 6 colors
representing the PCa foci frequencies, using an image posterization effect. We randomly defined 9 regions
in which the frequency of PCa foci and related pathologic findings were estimated.
Results: Evaluation of the spatial distribution of tumor foci according to Gleason score was enabled by
using a filter function for the score, as defined by the user. PCa foci with Gleason score (Gls) 6 were iden-
tified in 67.3% of the patients, of which 55 (48.2%) also had PCa foci with Gls between 7 and 10. Of 1173
PCa foci, 557 had Gls 6, whereas 616 PCa foci had Gls > 6. PCa foci with Gls 6 were mostly concentrated in
the posterior part of the peripheral zone of the prostate, whereas PCa foci with Gls > 6 extended toward
the basal and anterior parts of the prostate. The mean size of PCa foci with Gls 6 was significantly lower
than that of PCa with Gls > 6 (P < 0.0001).
Conclusion: The cMDX-based technical approach facilitates analysis of the topographical distribution of
PCa foci and related pathologic findings in prostatectomy specimens.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Prostate cancer (PCa) remains the most-diagnosed cancer in
men [1], and a majority of these patients undergo total prostate
removal (radical prostatectomy) [2]. The diagnosis of PCa is regu-
larly confirmed by prostate needle biopsy. However, there is a riskof missing PCa foci in needle biopsy, especially those located in the
anterior part of the prostate [3–5]. Rocco et al. concluded that the
sensitivity of double sextant biopsy for diagnosing clinically
significant PCa was 75% [3]. Another study found that PCa foci
missed by biopsy were clinically significant in 40% of patients
[5]. Furthermore, the cancer detection rate with repeat biopsies
varies from 10% to 20% [6]. The detection rate of prostate cancer
with prostate biopsy remains a central issue in urological oncology.
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sary to optimize the biopsy strategy.
The histopathological evaluation of prostatectomy specimens is
essential for decision-making and for predicting a patient’s out-
come [7]. Consequently, diverse standardized sectioning and docu-
mentation protocols for radical prostatectomy specimens have
been developed [7–9]. We applied a standardized protocol for
pathological reports according to Bettendorf et al. [9] (Fig. 1). Each
report contains personal data and clinical data (tumor classifica-
tion, grading, and malignancy) and a diagrammatic representation
of the histopathological findings in the prostate. This morphomet-
rical diagram of the prostate enables documentation of tumor-
extension patterns and the status of the surgical margins in radical
prostatectomy specimens. Additionally, an approximate estima-
tion of the absolute and relative tumor volumes is feasible using
this diagram [9,10]. Tumor volume is assumed to be an indepen-
dent predictor for biochemical recurrence in men with PCa after
radical prostatectomy [11].
The purpose of this article is to introduce a technical approach
to facilitate analysis of the topographical distribution patterns of
PCa foci and related pathological findings (Gleason score and foci
dimensions) in prostatectomy specimens. The technical approach
is based on cMDX (Clinical Map Document based on XML), which
is open source, meets Open Packaging conventions, and provides a
data-acquisition model for graphical and textual clinical informa-
tion. The graphical information is stored using a method based
on scalable vector graphics. cMDX has already been applied in
the reporting and analysis of PCa foci in prostatectomy specimens
[10].
In this context, the topographical distribution of PCa foci and
related pathologic findings were evaluated using the cMDX
documentation system [10,12]. Furthermore, we evaluated the
distribution of PCa foci in relation to their location within the pros-
tate. Our aim is to provide a technical approach to enable analysis
of the distribution of PCa foci in order to support studies related to
prostate biopsy and investigating diagnostic approaches to
improve detection rates in men with suspected PCa.2. Materials and methods
The current study was performed by the Department of Urology
at the University Hospital of Cologne between February 2012 and
March 2013. The study was performed within the scope of investi-
gating the distribution of Gleason scores within prostates affected
by PCa. The Gleason score represents the microscopic appearance
of the prostate cancer and is associated with the prognosis. The
topographical distribution of PCa and related pathologic evalua-
tions were documented using the cMDX documentation system
[10,12]. The project was performed in three steps. First, we ana-
lyzed the document architecture of cMDX, including textual and
graphical information. Second, we developed an evaluation model
supporting the topographic analysis of PCa foci and related patho-
logic parameters. Finally, we evaluated the analysis model in 168
consecutive prostatectomy specimens of men with diagnosed with
PCa who underwent total prostate removal. The surgical treat-
ments were performed by the Department of Urology at the
University Hospital of Cologne between 2008 and 2012. We retro-
spectively evaluated all prostatectomy specimens. A pathologist
(A.S.) performed the pathological evaluations.2.1. Analysis of document architecture
The cMDX document architecture consists of two types of con-
tent: patient-related data and template data (Fig. 2), as described
in our recent study [10]. Template data describe the anatomicalprostate schema designed by Bettendorf et al. and stored in
‘‘Mask.xml.” In addition, an XML document named ‘‘Tools.xml”
stores information defining drawing tools applied to sketch patho-
logical changes in scheme styles (e.g., freehand drawing) and pro-
vides parameters for the drawing tools [10].
The patient data consisted of two types of information. The first
was morphometrical information about histological changes (PCa,
high-grade prostatic intraepithelial neoplasia [HGPIN], and posi-
tive surgical margins) with additional textual descriptions (Glea-
son score, length of positive surgical margins). Each PCa focus
was related to pathologic findings (Gleason score and tumor vol-
ume percentage). The second type of information was clinical
and personal data in text form. Consequently, there are two XML
containers: ‘‘Form.xml” and ‘‘Map.xml.” ‘‘Map.xml” captures mor-
phometrical information about histological findings to reconstruct
them in schematic styles. The representation of the spread pattern
of PCa was based on vector graphics. An XML element called
‘‘Befund” was integrated into the CDATA-Section of a graphic
object showing a PCa focus. ‘‘Befund” captured information about
the histological patterns of the corresponding PCa focus. Form.
xml contained the element ‘‘Formular” with attributes containing
pathological findings and personal data. Pathological findings were
textual information not directly related to the morphometrical
data. Sensitive personal data were encrypted with Rijndael 256-
bit cryptography to avoid misuse.
2.2. Development of a cMDX-based analysis model for topographic
analysis
The following elements are required to develop a cMDX-based
data analysis model. First, the graphical information about the
tumor foci with the corresponding textual data (e.g. Gleason score
and tumor size) is stored in the electronic report. Second, a back-
ground layout contains graphical and textual information about
the prostate slices. Third, a filter layout defines the regions of inter-
est. Fourth, a search function to filter tumor foci meets the criteria
(e.g. Gleason score). Finally, a data-acquisition model is applied to
store the results for further analysis. The results should be transfer-
able to common analysis software. In cMDX document architec-
ture, the XML document ‘‘Map.xml” includes graphical
information about PCa foci with related pathological findings that
are required for topographical analysis. The XML document ‘‘Mask.
xml” defines the schematic diagram of the prostate gland. There-
fore, we focused on ‘‘Map.xml” and ‘‘Mask.xml” to integrate cMDX
into a data analysis model.
The data analysis model should facilitate analysis of the spatial
distribution of PCa foci and their pathological features inside the
prostate, as well as the generation of a heat map that represents
the distribution of PCa foci. Moreover, the model should enable
division of the prostate into regions of interest to analyze the pres-
ence status, frequency, and density of PCa foci in each region of
interest. For these purposes, we constructed three possible work-
flows of topographic analysis, as shown in Fig. 3. The first workflow
evaluated the association between pathologic findings (i.e. HGPIN
and PCa). The second workflow investigated the probability and
frequency of PCa foci present in defined regions of interest in the
prostate. The third workflow focused on tumor foci meeting the
search criteria (i.e. Gleason score) and investigated the probability
and frequency of the selected tumor foci in defined regions. The
Gleason score was divided into four groups: 6, 7a (3 + 4), 7b (4
+ 3), and 8–10. Several authors have stated that Gls 7b was associ-
ated with poorer clinical outcomes than Gls 7a [13,14].
To realize the analysis model, we designed a four-layer data
model based on cMDX, as shown in Fig. 4. The first layer defined
the background and the schematic diagram of the prostate and
required information provided by a cMDX template (Supplement
Fig. 1. An example of a pathological report including a diagrammatic representation of the histopathological findings in the prostate, and an example of a morphometric
mapping of a radical prostatectomy specimen showing an adenocarcinoma of the prostate in the left lobe with extracapsular tumor extensions and a positive surgical margin.
In addition to the Gleason system, the tumors are graded according to Helpap. Here, prostate cancer takes up about 15% of the total area of the prostate, which corresponds to
an estimated tumor volume of 7.5 cm3 in a prostate of 50 cm3. The computational estimation of tumor volume was performed as previously described by Eminaga et al. [10].
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Fig. 2. The components of the cMDX document architecture.
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of interest in the prostate stored in a cMDX document (Supplement
file 2). The third layer included information about the PCa foci
with related pathological findings obtained from cMDX-basedFig. 3. The diagram illustrated the work follow topathologic reports (Supplement file 3). The fourth layer showed
the results of topographical analysis in a heat map or pixel array
(Supplement files 4 & Fig. 6).
The 4-layer data model and filter function were integrated into a
cMDX Analyzer tool (Supplement file 5) and the incidence of PCa
was determined for each slice. A pixel grid was generated for each
slice to calculate the cumulative frequency of PCa foci (Supplement
file 6). When the filter function was applied, only PCa foci intersect-
ing with the regions of interest were considered for topographical
analysis (Fig. 5). Multiple filters can be defined by the user to deter-
mine the frequency of PCa in the region of interest. A heat map was
generated to represent the PCa distribution, which can be saved in
an image file format. The color gradient represents the frequency of
PCa in each pixel (red: highest frequency; blue: lowest frequency).
The cumulative frequency of PCa for each pixel located in the region
was calculated in parallel. A list containing the tumor-volume
percentage and the Gleason score of every PCa focus in each slice
or region of interest was generated. The results of the distribution
analysis were saved in the CSV (comma-separated values) file
format. The resulting data were exported into R (R Foundation for
Statistical Computing, Vienna, Austria) to determine the geometric
mean frequency of PCa per pixel, region, or slice. The density of PCa
foci per region was calculated by dividing the geometric mean
frequency of PCa into the number of prostatectomy speci-
mens included in the distribution analysis. The median, range,
and 95% confidence interval (CI) of the PCa frequency were also





Fig. 4. Four-layer visualization model. Workflow: (1) The filter layer registers pixels
affected by prostate cancer in regions of interest defined by the filter function. (2)
The mask layer defines the schematic diagrams. (3) The document layer represents
the graphical information from the cMDX document. (4) The background layer
contains background images with graphical descriptions.
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The cMDX pathology reports of 168 consecutive prostatectomy
(total prostate removal) specimens of men diagnosed with PCa
were considered for evaluation and validation of the data analysis
model. All prostatectomy specimens were retrospectively evalu-
ated as described elsewhere [10]. The cMDX tool was used to ana-
lyze the distribution of PCa and its related pathological parameters.
The topographical distribution of the tumor foci in the prostateOverall distribution of PCa foci with Gls 6
Fig. 5. The result of the topographical analysis bwas evaluated according to Gleason score and was presented as a
heat map. The color density of the heat map was reduced to six col-
ors in order to distinguish regions with different PCa frequencies
by using the image-posterization effect provided by the image-
processing software Paint.NET. After posterization, we focused on
regions showing one of the top three frequency classes of PCa
(red, yellow, or green; Fig. 6). We randomly defined nine regions
of interest inside the prostate and generated corresponding cMDX
documents using the cMDX Editor tool. To rollout a systematic
error by analyzing, we matched the distribution pattern of the
PCa foci to the heat map to determine the precision of the spatial
localizations of the foci for each of the 20 prostatectomy specimens
that were randomly selected. The locations of the PCa foci on the
heat map were evaluated in comparison to the original reports
before and after defining the region of interest. The precision was
calculated by dividing the number of intersected pixels into the
number of all pixels affected by PCa, and the duration of analysis
was estimated.3. Results
The analysis tool could successfully evaluate the spatial distribu-
tion of 168 prostatectomy specimens. The analysis of these cMDX
reports took 12 ± 2 seconds per filter. To evaluate the memory sta-
bility of the analysis tool, these filters were multiplexed up to 1000,
and the analysis was repeated 1000 times. The evaluation of the
spatial distribution of tumor foci according to their Gleason scores
was made feasible by using the filter function for the Gleason score
as defined by the user (Fig. 5). Data related to the surface size (given
as percentage), the slice location, and the Gleason scores of all of the
tumor foci were generated and stored in a CSV format and imported
into statistical software, such as SPSS and R.The tumor densities/frequencies in region of  interest 
efore and after applying the filter function.
High frequencyLow frequency
0 Gls6        43
Gls7a      35
Gls7b     15
Gls8-10  25
01-8 slGb7=3+4 slGa7=4+3 slG6 slG
Fig. 6. Distribution of prostate cancer according to Gleason Score. The frequency of tumor foci in the various locations are coded by colors: blue = low frequency, red = high
frequency. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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The implementation of the regional filter function enabled the
evaluation of tumor foci using the criteria defined by the user to
assist in determining the probability of tumor existence based on
certain pathological features in the defined regions. The criteria
consisted of the Gleason score and the availability of tumor foci
in the regions of interest. The user can define regions of interest
by drawing them on the schematic diagram of the prostate using
the cMDX Editor. A list of journal numbers for specimens with
tumor foci in these regions was generated. Using the journal num-
bers as a reference key enabled the merging lists from different
regions into a single table in R. The accuracy and precision analysis
showed that all pixels of tumor foci intersecting with the defined
regions were captured in 20 cases, even after repeating the analysis
three times.
The cMDX Editor was used to digitize 168 reports of radical
prostatectomy specimens. The computerized estimation showed
that the mean tumor volume was 7.5 cm3 (95% CI: 5.8–9.2). The
median age of the patients was 65 years at the time of prostatec-
tomy. Overall, most of the PCa foci were localized in the peripheral
zone of the apical half of the prostate. The frequency of PCa was
lower in the basal half of the prostate in comparison to the apical
half. PCa foci with Gls 6 were identified in 67.3% of the patients
(n = 114). Among these patients (48.2%), 55 also had PCa foci with
Gls between 7 and 10. Of 1173 PCa foci, 557 had Gls 6, whereas 616
PCa foci had Gls > 6. PCa foci with Gls 6 were mostly concentrated
in the posterior part of the peripheral zone of the prostate, whereas
PCa foci with Gls > 6 extended toward the basal and anterior parts
of the prostate (Fig. 6). The mean size of PCa foci with Gls 6 (0.340%
of the slice size; 95% CI: 0.30–0.39) was significantly lower than
those with Gls > 6 (2.1% of the slice size, 95% CI: 1.4–2.9)
(P < 0.0001). The odds ratio (OR) of the co-existence of a Gls 6
PCa (OR: 1.696; 95% CI: 0.839–3.428; P = 0.140) was higher inPCa foci with Gls 3 + 4 = 7 but not significantly, whereas OR for
the co-existence of Gls 6 PCa foci was significantly lower in foci
with Gls 4 + 3 = 7 and Gls 8–10 (OR: 0.196, 95% CI: 0.060–0.200;
P < 0.0001). In the regions of interest, we observed a variation in
the presence of PCa foci with Gls 3 + 3 = 6, between 27.9% and
47.0%. PCa foci with Gls 7a (3 + 4) were found at frequencies
between 32.1% and 11.1%. The frequency of PCa foci with Gls 7b
(4 + 3) ranged between 11.0% and 7.10%. PCa foci with Gls 8–10
was observed at a frequency ranging between 16.7% and 19.0% of
the total cases.
4. Discussion
Applying the cMDX documentation system facilitates analysis
of the spatial distribution of PCa foci and related pathological find-
ings. The size and location of each PCa focus can be determined,
and the volume estimation of the PCa foci can be calculated based
on Bettendorf’s scheme [9]. The spatial distribution of PCa foci can
be studied to optimize biopsy schemes or to analyze areas of the
prostate missed by conventional biopsies [3–5].
Sinnott et al. reported that PCa foci missed by biopsy were clin-
ically significant in 40% of patients [5]. Djavan et al. reported that
the cancer-detection rate on repeat biopsy varies from 10% to
20% [6]. The indication for repeat biopsies should be critically dis-
cussed. One in ten men refuse a repeat biopsy or require sedation
or analgesia due to pain, complications, and discomfort [15].
Therefore, researchers continue to develop strategies to improve
prostate biopsy detection rates and staging information. We suc-
cessfully performed two studies investigating the topographical
association between PCa and HGPIN (a presumable precursor of
PCa) and the prognostic significance of the location of extracapsu-
lar extensions or positive surgical margins in men with PCa, based
on the cMDX analysis system [16,17]. In addition, we could
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and identified that anterior tumors were frequent with increasing
PSA levels [18]. Furthermore, we investigated the spatial distribu-
tion of Gleason scores within the prostate to understand the patho-
genesis of PCa. Our findings confirm previous general descriptions
of the location of PCa foci inside the prostate [19,20].
Many computational approaches have been developed to recon-
struct the spatial distribution of PCa [20–24]. Thesemethods enable
the 3D reconstruction of PCa foci and were developed to optimize
the biopsy schema. For instance, Chen, Mazal, and Narayanan eval-
uated the spatial distribution of PCa by using a 3D reconstruction
model of the prostate to optimize the biopsy schema [20–22]. Addi-
tionally, Rojas et al. developed a 3D reconstruction of PCa to gener-
ate a spatial distribution of PCa foci inside the prostate and to
evaluate the spatial distribution according to clinical features such
as PSA level and age at diagnosis [25]. However, none of these
methods can analyze the spatial distribution of Gleason scores
within the prostate gland. Different Gleason patterns can be found
in a single prostatectomy specimen. The Gleason score consists of
the two patterns most often observed in a tumor focus. The final
pathology report includes the most-observed Gleason score in the
prostatectomy specimen. Therefore, a single tumor focus with a
higher Gleason score is not documented in the final report if PCa
foci with low Gleason scores are more frequent. There are indica-
tions that the tertiary Gleason pattern may influence the clinical
outcome and should be included in the final pathology report
[26,27]. Our approach can document all Gleason patterns observed
in the prostatectomy specimens and evaluate the spatial distribu-
tion of Gleason scores. The spatial distribution of Gleason scores
is valuable for a better understanding of the upgrading of a Gleason
score of 6. A Gleason score of 6 at biopsy is one of the criteria for
active surveillance as a treatment option in patients with low-risk
PCa. Understanding the spatial distribution of Gleason scores is nec-
essary to minimize the risk of Gleason score upgrading by identify-
ing regions of the prostate associated with an increased risk for
such upgrading. In our collective sample, Gleason score upgrading
was observed in prostatectomy specimens in 45.5% of PCa cases
with a Gleason score of 6 determined on prostate biopsy. Similar
results have been reported in other studies [28–30].
The computational reconstruction of PCa foci and the prostate is
time-intensive and expensive, making it unsuitable for routine
clinical use. All 3D-based reconstruction models are time- and
cost-intensive and require technical abilities that are not available
at most pathology institutes. A recent study concluded that the
cMDX system is suitable for the documentation of pathological
examinations of prostatectomy specimens and can be integrated
into the clinical routine [12]. In addition, the cMDX documentation
system enables analyses of the spatial distributions of PCa foci,
extracapsular extensions, and positive surgical margins, which
are visualized on a heat map without any major preparation. Extra-
capsular extensions and positive surgical margins are not consid-
ered in other computational methods [20–24]. The status of the
surgical margins plays an essential role in clinical decision-
making and quality-management assessments, which are impor-
tant conditions for the certification of prostate centers [31]. The
cMDX documentation system facilitates the extraction of clinical
and pathological data collected in the clinical routine, with respect
for privacy regulations [12].
We were able to evaluate the distribution of PCa foci and Glea-
son scores in defined regions by setting filters generated by the
cMDX Editor; 1000 filters can be applied by the analysis of the spa-
tial distribution of PCa foci and Gleason scores without the loss of
stability of the analysis tools. The Gleason score for each PCa focus
was assessed three times to avoid systematic errors. Using these
filters enabled the estimation of the frequency and density of PCa
foci in defined regions.Future work will be done to develop a computational approach
to generating a 3D reconstruction of the prostate with the spatial
distribution of PCa foci based on the cMDX documentation system.
We also plan to integrate genetic data into the cMDX document
architecture. The cMDX document architecture is extensible and
facilitates the integration of additional data for corresponding
tumor foci [10].
5. Limitations
This study focused primarily on the development of a tool to
enable the analysis of the spatial distribution of PCa in prostatec-
tomy specimens. The transferability of the cMDX analysis system
to other clinical fields is therefore limited. The technical approach
described here may be accompanied by technical failures, which
require appropriate handling to keep the system working without
interruption. The cMDX system is still being developed and may
require further enhancements in the future.
6. Conclusion
The cMDX system facilitates the analysis of the spatial distribu-
tion of PCa and related pathological findings. The applied tech-
nique supports a focus on certain regions of the prostate by
setting filters in the cMDX analyzer tool. Therefore, the analysis
of spatial distribution based on the cMDX documentation system
can be applied for research purposes.
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